Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
America’s Frontier Fund (AFF) is a non-profit strategic investment organization and venture capital firm dedicated to advancing United States leadership in "deep tech" sectors critical to national security and economic competitiveness. Founded in 2021 by high-profile technology leaders and former government officials, the fund focuses on the convergence of artificial intelligence, microelectronics, quantum science, advanced manufacturing, and biotechnology. AFF operates through multiple vehicles, including the Frontier Fund for early-stage investments and Roadrunner Venture Studios for incubation and pre-seed ventures. Its biotechnology strategy emphasizes synthetic biology, advanced biosynthesis, and resilient pharmaceutical supply chains, exemplified by investments in companies like Antheia and Revalia Bio. The firm bridges the gap between scientific discovery and commercial scaling by providing long-term capital and strategic government alignment. AFF is backed by a mix of philanthropic donations from figures like Eric Schmidt and Peter Thiel, as well as public-private capital partnerships.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on America's Frontier Fund.